PEPTIDESTAT
ApprovedWeight lossSubcutaneousEvidence 5/5

Semaglutide

Also known as: Ozempic, Wegovy, Rybelsus

Mimics the incretin GLP-1, slowing gastric emptying and reducing appetite while improving insulin secretion.

Browse guidesBuy / compare source
Semaglutide
Drug class
GLP-1 receptor agonist
Primary targets
GLP-1R
Dose reference
0.25–2.4 mg once weekly (SC); 3–14 mg daily (oral)
Half-life
~7 days
Developer / origin
Novo Nordisk
Reference year
2017
Evidence score
5/5 - Approved with large human trials

Approved uses

  • Type 2 diabetes
  • Chronic weight management
  • Cardiovascular risk reduction
Evidence 5/5

Approved with large human trials

Semaglutide has large randomized human trials and FDA-regulated labels across diabetes, obesity, and cardiovascular-risk contexts.

Approved medication with substantial human clinical evidence.

Evidence basis

  • Large human RCTs
  • FDA-regulated labeling
  • Approved GLP-1 receptor agonist

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

Semaglutide guides

Read the matching guide or adjacent research pages for more context.

What Is GLP-1? Complete Guide to the Hormone, the Drugs, and What They DoGLP-1 is a hormone your gut releases after eating. GLP-1 agonist drugs amplify its effect — slowing digestion, reducing appetite and improving blood sugar. This is the complete guide.Best GLP-1 for Weight Loss in 2026: Honest Head-to-HeadZepbound currently leads on average weight loss in trials. Wegovy has the best cardiovascular evidence. Here's the honest head-to-head of every approved GLP-1 for weight loss.GLP-1 for Weight Loss: The 2026 Complete GuideGLP-1 weight-loss drugs produce 8–21% average body-weight reduction in trials. Here's how to think about them honestly — eligibility, results, cost, side effects, and what happens when you stop.Retatrutide: What the Research Actually ShowsRetatrutide is an investigational triple-agonist peptide drawing major attention for weight loss. Here's what the clinical research actually shows.

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

Retatrutide

LY3437943

4/5
Weight lossInvestigational

Activates GLP-1, GIP and glucagon receptors simultaneously to suppress appetite and raise energy expenditure.

DetailsGuide

Tirzepatide

LY3298176, Mounjaro, Zepbound

5/5
Weight lossApproved

Activates GLP-1 and GIP receptors to improve glycemic control and reduce appetite + body weight.

Details

Liraglutide

Victoza, Saxenda

5/5
Weight lossApproved

Daily GLP-1 analog. Reduces appetite and improves glycemic control via the same incretin pathway as semaglutide.

Details
4/5
Weight lossInvestigational

Long-acting amylin analog that slows gastric emptying and reinforces satiety; studied in combination with semaglutide (CagriSema).

Details

Category hub

Open the category page for the full comparison table and FAQ.

Weight Loss Peptides

Compare weight loss peptides including GLP-1, GIP, amylin and triple-agonist compounds by approval status, mechanism, half-life and evidence score.

Research & educational purposes only

The information on PeptideStat is for educational and research purposes only and is not medical advice. Many peptides discussed are research compounds not approved for human use. Always consult a qualified healthcare professional before making any health decisions. Articles may contain affiliate links — we may earn a commission at no extra cost to you.